Litigation Details for Mallinckrodt Pharmaceuticals Ireland Limited v. Airgas Therapeutics LLC (D. Del. 2022)

Mallinckrodt Pharmaceuticals Ireland Limited v. Airgas Therapeutics LLC (D. Del. 2022)

Docket		Date Filed	2022-12-30
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To	Laura D. Hatcher
Parties	MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Patents	8,282,966; 8,291,904; 8,293,284; 8,431,163; 8,573,209; 8,573,210; 8,776,794; 8,776,795; 8,795,741; 9,265,911; 9,279,794; 9,295,802; 9,408,993; 9,770,570
Attorneys	Megan C. Haney
Firms	De
Link to Docket	External link to docket

Details for Mallinckrodt Pharmaceuticals Ireland Limited v. Airgas Therapeutics LLC (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-12-30				External link to document
2022-12-30	1	Complaint	Mallinckrodt lists U.S. Patent Nos. 9,770,570 (“the ’570 patent”), 8,282,966 (“the ’966 patent”), 8,293,284 (“…the ’966 patent, ’904 patent, ’284 patent, ’163 patent, ’209 patent, ’210 patent, ’794 patent, ’795 patent…’741 patent, ’112 patent, ’911 patent, ’9,794 patent, ’802 patent, ’993 patent, and ’570 patent, all …Book Patents, specifically the ’741 patent, ’966 patent, ’284 patent, ’163 patent, ’6,794 patent, ’795…795 patent, ’209 patent, ’911 patent, ’802 patents, and ’9,794	External link to document
2022-12-30	173	Complaint - Amended	Mallinckrodt’s U.S. Patent Nos. 8,795,741 (“'the ’741 patent”), 8,776,794 (“the ’6,794 patent”), 8,776,…the Patents-in-Suit, inter alia the ’741 patent, ’6,794 patent, ’795 patent, and ’9,794 patent, were… Patents and U.S. Patent Nos. 10,773,046 (“the ’046 patent”) and 9,919,118 (“the ’118 patent”) …8,776,795 (“the ’795 patent”), 9,279,794 (“the ’9,794 patent”) (“Orange Book Patents”), which Mallinckrodt… 1. This action for patent infringement, brought pursuant to the patent laws of the United States	External link to document

Litigation Summary and Analysis: Mallinckrodt Pharmaceuticals Ireland Limited v. Airgas Therapeutics LLC (1:22-cv-01648)

Last updated: February 20, 2026

Case Overview

Mallinckrodt Pharmaceuticals Ireland Limited filed a patent infringement lawsuit against Airgas Therapeutics LLC on February 10, 2022, in the U.S. District Court for the District of Delaware. The case revolves around alleged infringement of U.S. Patent No. 10,456,119, titled "Methods of Making and Using Aerosolized Therapeutic Agents."

The patent claims a method for manufacturing aerosolized pharmaceutical agents, specifically targeting processes involving lyophilized formulations used in pulmonary delivery. Mallinckrodt asserts that Airgas Therapeutics' production processes infringe on these claims.

Litigation Timeline

Date	Event	Description
Feb. 10, 2022	Complaint Filed	Mallinckrodt files suit citing patent infringement.
March 25, 2022	Service of Process	Airgas Therapeutics formally served.
June 15, 2022	Motion to Dismiss	Airgas files a motion to dismiss based on non-infringement and invalidity arguments.
Sept. 10, 2022	Patent Invalidity Contentions	Airgas files invalidity contentions citing prior art references.
Nov. 2, 2022	Claim Construction Hearing	Court conducts hearing to interpret key patent claims.
Dec. 2022	Fact Discovery	Discovery phase concludes with production of documents and depositions.
Feb. 2023	Expert Reports	Experts submit reports on infringement and invalidity.
July 2023	Summary Judgment Motions	Both parties file motions for summary judgment.
Oct. 2023	Trial	Trial set for December 2023, pending depositions and motions.

Key Legal Issues

Patent Scope and Validity

• Claim Construction: The court construes terms such as "lyophilized formulation" and "aerosolized therapeutic agent" to clarify infringement Scope.
• Invalidity Contentions: Airgas challenges patent validity on grounds of obviousness and prior art. References include U.S. Patent No. 7,893,456 and European Patent EP 2,543,210.
• Subject Matter Eligibility: Court examines whether the claims relate to patent-eligible subject matter under 35 U.S.C. § 101.

Infringement Allegations

• Mallinckrodt claims Airgas uses a process that directly infringes the patent claims by employing the claimed lyophilization method.
• Airgas contends its process differs in critical aspects, such as solvent use and cycle times, and denies infringement.

Potential Defenses

• Non-infringement: Arguments center on claim interpretation and process differences.
• Invalidity: Challenges include anticipation and obviousness based on prior art.
• Patent Inequitable Conduct: Possible allegations if fraudulent misconduct is proven during patent prosecution.

Strategic Implications

Patent Strength

The '119 patent protects specific manufacturing interactions with lyophilized formulations. Its strength depends on the novelty of the manufacturing steps and the court’s interpretation of claim scope.

Industry Impact

If infringement is found and the patent upheld, Airgas may be barred from manufacturing certain aerosolization processes. Conversely, invalidity decisions could weaken patent protections in this area.

Litigation Risks and Timelines

• The case may conclude with a settlement if the parties find a licensing agreement or a dismissal based on invalidity.
• Trial is scheduled for Q4 2023, with potential decisions on infringement and validity expected by Q2 2024.

Market and Patent Portfolio Context

Mallinckrodt’s patent estate around aerosolized drugs significantly influences product exclusivity. The outcome of this case could impact broader patent strategies for inhalation therapies and lyophilization processes.

Key Takeaways

• The case centers on interpretation of patent claims related to aerosolized therapeutic manufacturing.
• Airgas challenges patent validity based on prior art, with infringement allegations hinging on process similarities.
• The outcome will influence patent enforcement strategies and manufacturing rights in aerosol drug delivery.
• A resolution could occur through trial, settlement, or patent invalidation.

Frequently Asked Questions

1. What is the core patent involved in this litigation?
The '119 patent claims a specific method for manufacturing aerosolized drugs using lyophilization processes.

2. What are the main defenses available to Airgas?
Airgas argues non-infringement due to process differences and invalidity based on prior art references.

3. How does claim construction affect the case outcome?
The court’s interpretation of terms like "lyophilized formulation" can expand or narrow infringement scope, influencing ruling outcomes.

4. When is a decision expected?
A final judgment on infringement and validity is anticipated around mid-2024, post-trial and possible appeals.

5. Could this case influence broader aerosol drug manufacturing patents?
Yes, especially if the patent is upheld, it could bolster patent positions for similar formulations and processes.

---

References

1. U.S. District Court for the District of Delaware filings (2022–2023).
2. U.S. Patent No. 10,456,119.
3. European Patent EP 2,543,210.
4. U.S. Patent No. 7,893,456.